Back to Agenda
RWE4 Decisions
Session Chair(s)
Karen Facey, PhD
Visiting Senior Research Fellow
University of Edinburgh, United Kingdom
HTA/Payer decisions about pricing and reimbursement are becoming increasingly difficult as treatments come to market via expedited regulatory approvals with limited evidence from traditional clinical development programmes. There is interest in the use of real-world data (RWD) to inform deliberations about the added value of these new technologies, but recognition that payers need to be clear about the questions such RWD could answer and what real-world evidence could really inform decision-making. This workshop will discuss a suite of RWD initiatives led by the Belgian payer, INAMI and consider the establishment of a new multi-stakeholder learning network to test the specific case of highly innovative technologies.
Speaker(s)
Panelist
Peter Richard Arlett, MD, FFPM, FRCP
European Medicines Agency, Netherlands
Head Data Analytics and Methods Task Force
Panelist
Adrian Jonas
NICE, United Kingdom
Associate Director for Data and Analytics
Panelist
Angèl Link, MSc
ZIN (dutch Health Care Institute), Netherlands
Senior advisor and deputy secretary Appraisal committee
Panelist
Jo De Cock
National Institute of Health and Disability Insurance, Belgium
CEO
Have an account?